###begin article-title 0
Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 627 634 627 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 636 641 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 643 648 643 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSPT1</italic>
###xml 650 655 650 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST</italic>
###xml 657 660 657 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 662 666 662 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NES1</italic>
###xml 668 676 668 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAR&#946;2</italic>
###xml 682 686 679 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 125 130 <span type="species:ncbi:9606">human</span>
Estrogen receptor (ER)-positive breast cancers are considered prognostically more favorable than ER-negative tumors, whereas human epidermal growth factor receptor (HER)2/neu-positive breast cancers are associated with worse prognosis. The objective of the present study was to determine whether ER-positive and ER-negative status relates to epigenetic changes in breast cancer-related genes. To evaluate epigenetic differences in tumor-related genes relating to ER and HER2/neu status of primary tumors, we examined the promoter methylation status of the promoter region CpG islands of eight major breast tumor-related genes (RASSF1A, CCND2, GSPT1, TWIST, APC, NES1, RARbeta2, and CDH1).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 20 21 20 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 45 47 45 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Paired ER-positive (n = 65) and ER-negative (n = 65) primary breast tumors (n = 130) matched for prognostic factors were assessed. DNA was extracted from paraffin-embedded tumor tissue after microdissection, and methylation-specific PCR and capillary-array electrophoresis analysis were performed.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 50 58 50 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2 </italic>
###xml 88 90 88 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 374 381 374 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 383 388 383 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 394 398 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 411 413 411 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 423 425 423 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 439 441 439 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
In early stages of tumor progression (T1 and N0), RASSF1A and CCND2 were significantly (P < 0.05) more methylated in ER-positive than in ER-negative tumors. GSTP1 hypermethylation was more frequent in the lymph node metastasis positive group than in the negative group. Double negative (ER-negative, HER2/neu-negative) breast cancers had significantly lesser frequencies of RASSF1A, GSTP1, and APC methylation (P < 0.0001, P < 0.0001, and P = 0.0035, respectively). Both ER and HER2/neu status correlated independently with these epigenetic alterations.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 264 272 <span type="species:ncbi:9606">patients</span>
We demonstrated significant differences in tumor-related gene methylation patterns relevant to ER and HER2/neu status of breast tumors. This may be of significance in the assessment of targeted therapy resistance related to ER and HER2/neu status in breast cancer patients.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Hypermethylation is an epigenetic change that blocks the promoter region of a gene and results in gene silencing. In breast cancer, tumor-related genes may be silenced by hypermethylation; many hypermethylated genes have been reported, and silencing of these genes plays important roles in carcinogenesis and tumor progression [1-3]. Identification of epigenetic changes and their correlation with other clinical factors could lead to improvements in cancer diagnosis and treatment.
###end p 11
###begin p 12
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 370 371 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 919 921 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 412 420 <span type="species:ncbi:9606">patients</span>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
In patients with breast cancer, estrogen receptor (ER) status is an important treatment and prognostic factor. Breast cancer patients with ER-positive tumors generally have a more favorable prognosis than do those who have ER-negative tumors. These breast cancer patients can be treated successfully with hormonal therapies such as tamoxifen and aromatase inhibitors [4-9]. Epidemiological studies revealed that patients with ER-positive tumors have risk profiles different from patients with ER-negative tumors. Parity and timing of births were inversely associated with ER-positive tumors, but not with ER-negative tumors, and body mass index after menopause was more strongly associated with ER-positive than with ER-negative tumors [10]. In addition, rates of ER-positive breast cancer incidence have been shown to increase after age 50 to 54 years, whereas the rates of ER-negative breast cancer incidence do not [11].
###end p 12
###begin p 13
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
Similarly, differences in the gene expression patterns of ER-positive and ER-negative tumors have been documented in microarray expression studies, which identified profile differences in breast tumor subtypes [12,13]. These findings suggest that ER status of breast cancer represents distinct phenotypes. However, few studies have determined epigenetic changes in tumor-related genes in relation to ER status in matched-paired breast cancers.
###end p 13
###begin p 14
To investigate the epigenetic differences between ER-positive and ER-negative breast cancer, we assessed the methylation frequency of several breast tumor-related genes that are known to undergo hypermethylated changes in breast cancer, and that play important roles in tumorigenesis and cancer progression. The objective of the study was to determine the association between ER status and epigenetic changes in these tumor-related genes.
###end p 14
###begin p 15
###xml 36 44 36 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2 </italic>
###xml 156 162 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 222 228 222 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST </italic>
###xml 309 313 309 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 374 379 374 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NES1 </italic>
###xml 469 478 469 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAR&#946;2 </italic>
###xml 571 579 565 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 696 698 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 847 849 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 850 852 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 970 972 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1069 1071 1063 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1171 1173 1165 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1191 1197 1185 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2 </italic>
###xml 1291 1293 1285 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1457 1459 1451 1453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1498 1504 1492 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1613 1615 1607 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1727 1733 1721 1727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST </italic>
###xml 1780 1782 1774 1776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1783 1785 1777 1779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1910 1914 1904 1908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1996 1998 1990 1992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1999 2001 1993 1995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 2004 2009 1998 2003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NES1 </italic>
###xml 2089 2091 2083 2085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 2092 2094 2086 2088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 2097 2106 2091 2097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAR&#946;2 </italic>
###xml 2151 2160 2142 2148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAR&#946;2 </italic>
###xml 2214 2216 2202 2204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 2311 2313 2299 2301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 2520 2522 2508 2510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 229 234 <span type="species:ncbi:9606">human</span>
###xml 2650 2658 <span type="species:ncbi:9606">patients</span>
The genes assessed were as follows: RASSF1A (RAS association domain family 1A; location: 3p21.3; GenBank: ), CCND2 (cyclin D2; location: 12p13; GenBank: ), GSTP1 (glutathione S-transferase P1; location: 11q13; GenBank: ), TWIST (human basic helix-loop-helix DNA binding protein; location: 7p21.2; GenBank: ), APC (adenomatous polyposis coli; location: 5q21-q22; GenBank: ), NES1 (normal epithelial cell-specific 1 or kallikrein 10; location: 19q13.3-q13.4; GenBank: ), RARbeta2 (retinoic acid receptor-beta2; location: 3p24; GenBank: ), and CDH1 (E-cadherin; GenBank: ). RASSF1A is a putative tumor-suppressor gene that is frequently inactivated epigenetically rather than in a mutational event [14]. A direct correlation between promoter region methylation and loss of expression has been shown in many tumor cell lines, including breast cancer [15-18]. RASSF1A can exert a tumor-suppressing effect by blocking oncogene-mediated c-Jun amino-terminal kinase activation [19]. It also associates with microtubules and contributes to the maintenance of genomic stability [20]. Loss of CCND2 expression caused by methylation is an early event in breast cancer tumorigenesis [21]. Methylation of CCND2 has been correlated with poor prognosis, implying that CCND2 has a tumor-suppressor function [22]. GSTP1 is one of a family of enzymes that detoxifies hydrophobic electrophiles, and may be part of a protection system from environmental or dietary carcinogens [23]. Our group has previously found that GSTP1 methylation correlates with increased tumor size and increased likelihood of sentinel lymph node metastases [24]. TWIST induces E-cadherin mediated cell-cell adhesion and induction of cell motility. Increased expression of TWIST correlates with tumor invasion and metastasis [25,26]. APC gene germline mutations have been shown to be associated with familial adenomatous polyposis. Hypermethylation of the APC promoter is also associated with breast cancer, especially lobular breast cancer [27-29]. NES1 is a putative tumor suppressor gene found to be downregulated in breast cancer [30,31]. RARbeta2 is postulated to be a tumor suppressor gene. RARbeta2 methylation correlates with breast cancer metastasis [32]. It is through retinoic acid receptors that retinoids can prevent primary tumor progression [33]. CDH1 expression reduction is regarded as one of the main molecular events involved in dysfunction of the cell-cell adhesion system, triggering cancer invasion and metastasis. Mahler-Araujo and coworkers [34] reported a correlation between negative or reduced CDH1 expression and lack of ER expression in tumors from 245 breast cancer patients.
###end p 15
###begin p 16
This study was conducted to investigate epigenetic differences in specific tumor-related genes between ER-positive and ER-negative breast cancers. We hypothesized that ER-positive breast tumors have different epigenetic profiles of tumor-related genes during early stages of cancer progression. We examined the methylation status of eight genes suspected of being involved in regulation of breast cancer, and investigated the methylation status of those genes at different stages of tumor development. We compared the methylation status of these genes between ER-positive and ER-negative breast tumors in early and advanced stages to investigate whether epigenetic changes occur in early stages of primary tumor progression.
###end p 16
###begin p 17
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human epidermal growth factor receptor (HER)2/neu is an important factor for treatment and prognosis. HER2/neu over-expression occurs in 15% to 25% of breast tumors and is associated with poor prognosis and resistance to hormonal therapy [35-37]. HER2/neu and ER expression have been reported to exhibit an inverse correlation [9,38,39]. Furthermore, previous reports have demonstrated the effect of estrogen on downregulation of HER2/neu production [40]. We investigated the epigenetic differences between HER2/neu-positive and HER2/neu-negative breast tumors relative to ER status and further identified the epigenetic characteristics of ER-negative, HER2/neu-negative (double-negative) breast tumors.
###end p 17
###begin title 18
Materials and methods
###end title 18
###begin title 19
###xml 10 17 <span type="species:ncbi:9606">patient</span>
Tumor and patient selection
###end title 19
###begin p 20
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 103 110 <span type="species:ncbi:9606">patient</span>
###xml 570 575 <span type="species:ncbi:9606">human</span>
Sixty-five paraffin-embedded, invasive ER-negative and ER-positive breast tumor pairs were matched for patient age, tumor size (T stage), nodal status (lymph node [LN] metastasis positive or negative), and presence or absence of distant metastases (M status). The primary tumor characteristics are listed in Tables 1 and 2. HER2/neu status was originally scored 0 to 3+, and 0 and 1+ tumors were regarded as HER2/neu negative. Tumors were graded and staged according to the American Joint Committee on Cancer 6th Edition Guidelines [41]. Informed consent for use of all human specimens in this study was obtained under a protocol approved by Saint John's Health Center (Santa Monica, CA, USA)/John Wayne Cancer Institute institutional review board.
###end p 20
###begin p 21
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient and tumor characteristics
###end p 21
###begin p 22
###xml 28 33 <span type="species:ncbi:9606">human</span>
ER, estrogen receptor; HER, human epidermal growth factor receptor.
###end p 22
###begin p 23
Clinical factors by HER2/neu status
###end p 23
###begin p 24
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4 6 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 25 26 23 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 38 43 <span type="species:ncbi:9606">human</span>
achi2 test and Student's t-test. HER, human epidermal growth factor receptor; NS, not significant.
###end p 24
###begin title 25
DNA processing and methylation-specific PCR
###end title 25
###begin p 26
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 838 839 831 832 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1052 1054 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1055 1057 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1120 1127 1113 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 1129 1132 1122 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1134 1139 1127 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST</italic>
###xml 1141 1145 1134 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 1147 1152 1140 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 1154 1158 1147 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NES1</italic>
###xml 1160 1165 1153 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 1171 1179 1164 1169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAR&#946;2</italic>
###xml 1237 1241 1227 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 1456 1457 1446 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
DNA was extracted as previously described [24]. Briefly, paraffin-embedded primary tumor specimen blocks were sectioned at 10 mum and deparaffinized in 100% xylene, followed by a 100% ethanol incubation, and stained with hematoxylin and eosin. Tumor tissue was microdissected in comparison with a similarly stained and cover-slipped reference slide cut from each tissue block. DNA preparation buffer containing 50 mmol/l Tris, 1 mmol/l EDTA, 2.5% Tween-20, and Proteinase K (QIAGEN, Valencia, CA, USA) was added to microdissected tissue and incubated at 50degreesC overnight. DNA was extracted from the aqueous layer using phenol-chloroform-isoamyl alcohol (25:24:1; Fisher Scientific, Pittsburgh, PA, USA) and precipitated using pellet paint NF co-precipitant (Novagen, Madison, WI, USA). DNA was resuspended in molecular biology grade H2O (Fisher Scientific). DNA quantification was performed on all specimens using the PicoGreen quantification assay (Molecular Probes, Eugene, OR, USA). Bisulfite modification was performed as previously described [15,24]. A panel of eight genes was assessed for methylation status: RASSF1A, APC, TWIST, CDH1, GSTP1, NES1, CCND2, and RARbeta2. Methylation-specific PCR (MSP) was performed using AmpliTaq Gold DNA polymerase (Perkin Elmer, Norwalk, CT, USA) and 50 pmol each of forward and reverse primers for methylated (M) and unmethylated (U) sequences. Primer sequences for MSP of the eight genes are shown in Table 3.
###end p 26
###begin p 27
Primer sequences for MSP
###end p 27
###begin p 28
MSP, methylation-specific PCR.
###end p 28
###begin p 29
###xml 377 379 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 380 382 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
PCR was carried out after optimizing annealing temperatures for each primer set to include 40 timed cycles of denaturation at 94degreesC for 30 seconds, annealing for 30 seconds, and extension at 72degreesC for 30 seconds. Post-MSP product analysis was performed using capillary array electrophoresis (CEQ 8000XL, Beckman Coulter, Fullerton, CA, USA), as described previously [15,24].
###end p 29
###begin title 30
Statistical analysis
###end title 30
###begin p 31
###xml 107 109 105 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 435 437 433 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 46 53 <span type="species:ncbi:9606">patient</span>
Descriptive statistics were used to summarize patient characteristics and gene hypermethylation status. chi2 test and Fisher's exact test were used to compare methylation status between ER-positive and ER-negative subgroups, and to compare those differences according to clinical factors, such as tumor size (T stage) and nodal status (N stage). All statistical analyses were carried out using the SAS system (SAS, Cary, NC, USA), and P < 0.05 was considered statistically significant.
###end p 31
###begin title 32
Results
###end title 32
###begin title 33
Methylation status of genes in ER-negative and ER-positive tumors
###end title 33
###begin p 34
###xml 173 175 171 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 301 302 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 308 315 306 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 317 322 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 324 329 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 331 336 329 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST</italic>
###xml 342 346 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 544 548 542 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NES1</italic>
###xml 550 558 548 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAR&#946;2</italic>
###xml 564 568 559 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 708 709 703 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 794 801 789 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 803 808 798 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 810 815 805 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 817 822 812 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST</italic>
###xml 828 831 823 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1246 1252 1241 1247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1356 1357 1351 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 1361 1362 1356 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T7">7</xref>
Initially, the difference in methylation status of eight genes between the age-matched and tumor background-matched ER-negative and ER-positive groups was analyzed using chi2 tests. A representative example of methylated and unmethylated gene analysis from paraffin-embedded tissue is shown in Figure 1. For RASSF1A, CCND2, GSTP1, TWIST, and APC genes, the proportion of methylated genes was significantly higher in the ER-positive than in the ER-negative tumor group. However, no significant differences in methylation status were detected in NES1, RARbeta2, and CDH1. Among the eight biomarkers studied, none exhibited predominance of methylation status in ER-negative tumors by univariate analysis (Table 4). Based on this finding, we conducted further analysis of the methylation status of RASSF1A, CCND2, GSTP1, TWIST, and APC. Second, we analyzed the differences in the methylation status of these five tumor-related genes between premenopausal and postmenopausal, T1 and T2/T3, and LN metastasis negative (N0) and positive (N1/N2) subgroups using univariate analysis. Among these five genes, there were no significant differences in methylation frequency between premenopausal and postmenopausal subgroups and T1 and T2/T3 subgroups. Only GSTP1 exhibited significantly more frequent methylation in the N1/N2 subgroup than in the N0 subgroup (Tables 5 to 7).
###end p 34
###begin p 35
Comparison of primary tumor gene methylation status relative to ER status
###end p 35
###begin p 36
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4 6 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
achi2 test or Fisher's exact test was used appropriately. ER, estrogen receptor; NS, not significant.
###end p 36
###begin p 37
###xml 64 71 <span type="species:ncbi:9606">patient</span>
Comparison of primary tumor gene methylation status relative to patient menopausal status
###end p 37
###begin p 38
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4 6 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
achi2 test. NS, not significant.
###end p 38
###begin p 39
Comparison of primary tumor gene methylation status relative to T stage
###end p 39
###begin p 40
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4 6 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
achi2 test. NS, not significant.
###end p 40
###begin p 41
Comparison of primary tumor gene methylation status relative to nodal status
###end p 41
###begin p 42
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4 6 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
achi2 test. NS, not significant.
###end p 42
###begin p 43
Methylated and unmethylated markers. Presented are representative methylation-specific PCR results of biomarker RASSF1A from a paraffin-embedded archival breast tissue specimens, showing methylated and unmethylated markers. bp, base pairs.
###end p 43
###begin title 44
Methylation status of genes in ER-negative and ER-positive early-stage tumors
###end title 44
###begin p 45
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T8">8</xref>
###xml 495 503 495 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 507 513 507 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2 </italic>
###xml 543 549 543 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 553 559 553 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST </italic>
To study further the changes in tumor-related gene methylation status of both ER-positive and ER-negative breast cancers during tumor progression, we investigated the difference between both ER-positive and ER-negative primary tumors based on American Joint Committee on Cancer T and N stages. First, we compared the methylation status of five different genes in ER-negative and ER-positive tumors for T1c and T2/T3 stages (Table 8). The ER-positive group exhibited more frequent methylation of RASSF1A and CCND2 in both T1c and T2/T3 stages. GSTP1 and TWIST were more methylated in the ER-positive group in the T1c stage, but the differences did not achieve statistical significance. However, they showed significant differences in T2/T3 stage. We examined changes in the methylation frequency ratio (methylation frequency of gene in the ER-positive group/methylation frequency of gene in the ER-negative group) for each tumor-related gene during tumor progression. No difference in the methylation frequency ratio was observed between T1c and T2/T3 stages for all tumor-related genes assessed.
###end p 45
###begin p 46
Methylated primary ER-negative and ER-positive tumors: T1c and T2/T3 subgroups
###end p 46
###begin p 47
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4 6 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
achi2 test or Fisher's exact test was used appropriately. ER, estrogen receptor; NS, not significant.
###end p 47
###begin p 48
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T9">9</xref>
###xml 206 208 206 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 245 252 245 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 254 259 254 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 265 271 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 300 306 300 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST </italic>
###xml 310 314 310 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
Next, we investigated the difference in methylation of tumor-related genes between the ER-negative and ER-positive subgroups of N0 and N1/N2 tumors (Table 9). The ER-positive group exhibited significantly (P < 0.05) more frequent methylation of RASSF1A, CCND2, and GSTP1 in both N0 and N1/N2 stages. TWIST and APC were more frequently methylated in the ER-positive group in the N0 stage, but not significantly. Similar to subgroups divided by T stage, there were no differences in methylation frequency ratio for all genes assessed between the N0 and N1/N2 subgroups.
###end p 48
###begin p 49
Methylated primary ER-negative and ER-positive tumors: N0 and N1/N2 subgroups
###end p 49
###begin p 50
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4 6 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
achi2 test or Fisher's exact test was used appropriately. ER, estrogen receptor; NS, not significant.
###end p 50
###begin title 51
Methylation status of tumor-related genes relevant to HER2/neu status
###end title 51
###begin p 52
###xml 537 544 537 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 546 551 546 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 557 561 557 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 728 733 728 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST</italic>
###xml 735 739 735 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NES1</italic>
###xml 741 749 741 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAR&#946;2</italic>
###xml 755 760 752 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 798 803 795 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1 </italic>
###xml 903 905 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T10">10</xref>
###xml 1107 1110 1104 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1112 1117 1109 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 1119 1126 1116 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 1132 1138 1129 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST </italic>
###xml 1145 1147 1142 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T11">11</xref>
###xml 1254 1257 1251 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1259 1264 1256 1261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 1270 1278 1267 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
In addition to ER, we investigated differences in methylation status of the eight genes between the HER2/neu-negative and HER2/neu-positive tumor groups. First, we analyzed the relation between ER status and HER2/neu status. Using matched samples, no difference was found in the frequency of HER2/neu-positive tumors between the ER-negative and ER-positive groups. Then, the differences in methylation status of all eight genes were analyzed between the HER2/neu-positive and HER2/neu-negative tumor groups. The proportion of methylated RASSF1A, GSTP1, and APC genes was significantly greater in the HER2/neu-positive than in the HER2/neu-negative tumor group; no significant differences in methylation status were detected for TWIST, NES1, RARbeta2, and CCND2. Among the eight biomarkers studied, CDH1 showed predominance of methylation status in HER2/neu-negative tumors by univariate analysis (Table 10). Next, we compared the methylation status of double-negative tumors versus breast cancers expressing either ER or HER2/neu. The double-negative breast cancer group showed less frequent methylation of APC, GSTP1, RASSF1A, and TWIST (Table 11). Logistic regression analysis revealed that both ER and HER2/neu status affect the methylation status of APC, GSTP1, and RASSF1A independently.
###end p 52
###begin p 53
Comparison of primary tumor gene methylation status relative to HER2/neu status
###end p 53
###begin p 54
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4 6 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 63 68 <span type="species:ncbi:9606">human</span>
achi2 test or Fisher's exact test was used appropriately. HER, human epidermal growth factor receptor; NS, not significant.
###end p 54
###begin p 55
Comparison of primary tumor gene methylation status relative to double-negative breast cancers versus cancers expressing either ER or HER2/neu
###end p 55
###begin p 56
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4 6 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 107 112 <span type="species:ncbi:9606">human</span>
achi2 test or Fisher's exact test was used appropriately. ER, estrogen receptor; NS, not significant; HER, human epidermal growth factor.
###end p 56
###begin title 57
Relation between the tumor-related genes with respect to methylation status
###end title 57
###begin p 58
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T12">12</xref>
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 182 190 182 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 194 200 194 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST </italic>
###xml 306 312 306 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2 </italic>
###xml 316 320 316 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 514 516 514 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The relation between the genes with respect to methylation status is shown in Table 12. GSTP1 methylation frequency is significantly related to methylation frequency of other genes. RASSF1A and TWIST methylation frequencies were significantly related to methylation frequency of three of four other genes. CCND2 and APC methylation frequency related with two of four other genes. In total, we examined 10 different relationships among five genes; seven of the 10 correlations (70%) were statistically significant (P < 0.05).
###end p 58
###begin p 59
The relation between the methylated genes relative to methylation status
###end p 59
###begin p 60
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4 6 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
achi2 test. NS, not significant.
###end p 60
###begin title 61
Discussion
###end title 61
###begin p 62
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 309 310 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 382 383 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 798 805 <span type="species:ncbi:9606">patient</span>
During the past several years, new molecular biomarkers have been discovered that are important targets for the diagnosis and therapy of breast cancer [3,42]. ER and HER2/neu are important prognostic biomarkers and therapeutic targets in primary breast cancer. ER-negative tumors appear to be more malignant [4,7,8,43], resulting in a poorer prognosis than with ER-positive tumors [5,9,44]. The present study was conducted to identify differences in epigenetic events related to ER expression by infiltrating breast cancer. To date, few studies have rigorously assessed matched paired ER-negative and ER-positive primary breast tumors for epigenetic differences. We focused on the epigenetic differences between ER-positive and ER-negative breast cancers, and used tumor specimen pairs matched for patient age, size, nodal status, and presence or absence of distant metastases. This sampling enabled rigorous analysis, and the results imply that epigenetic features of ER-positive tumors are different from those of ER-negative tumors.
###end p 62
###begin p 63
###xml 29 30 29 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 230 237 230 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 239 244 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 253 258 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST</italic>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 419 425 419 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST </italic>
###xml 462 467 462 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1 </italic>
###xml 587 595 587 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAR&#946;2</italic>
###xml 597 602 594 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 608 613 605 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1 </italic>
###xml 1127 1129 1124 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
###xml 500 508 <span type="species:ncbi:9606">patients</span>
Widschwendter and coworkers [3] demonstrated that methylation of APC correlated with ER positivity. Our data are consistent with this previous report. Furthermore, we demonstrated a significant difference in methylation status of RASSF1A, CCND2, GSTP1, TWIST, and APC between the ER-positive and ER-negative groups. In contrast, Li and colleagues [45] reported that ER-positive patients exhibited a higher frequency of TWIST methylation and a lower frequency of CDH1 methylation than did ER-negative patients. They also found no significant differences in the methylation frequencies of RARbeta2, CCND2, and CDH1 between ER-positive and ER-negative groups. The reason for the dissimilarity in study findings may be due to differences in methylation analysis; Li and colleagues assessed methylated PCR products by gel electrophoresis, which is more subjective and less sensitive than capillary array electrophoresis analysis of methylated PCR products. The discrepancy may also have resulted from differences in the approach to the particular specimens assessed. Because methylation and ER status change with tumor progression [25], care should be taken when sampling ER-positive and ER-negative tumors to evaluate epigenetic changes and clinical associations.
###end p 63
###begin p 64
###xml 271 279 271 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 283 288 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 722 728 722 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 776 778 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 980 986 980 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1128 1136 1128 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 1140 1146 1140 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2 </italic>
To clarify when differences in methylation status between ER-positive and -negative tumors occur, we compared differences in methylation status between T1c and T2 stage subgroups. The ER-positive group exhibited significantly more frequent hypermethylation of two genes (RASSF1A and CCND2), independent of T stage. Moreover, the ratio of methylation frequency does not differ between T1c and T2/T3 stage subgroups. This observation indicates that the differences in methylation patterns do not significantly change when breast tumors progress from T1c to T2/T3 stage. Similarly, no difference in the methylation frequency ratio was detected between LN metastasis negative and positive tumors. Previously, we reported that GSTP1 hypermethylation correlates with LN metastasis [24]. Similarly in this study, only GSTP1 hypermethylation was found to be more frequent in the LN metastasis positive group than in the negative group. In both LN metastasis positive and negative groups, GSTP1 hypermethylation was found to be more common in ER-positive than in ER-negative tumors. Furthermore, the differences in methylation status of RASSF1A and CCND2 between the ER-positive and ER-negative groups can be recognized in early stages of cancer, such as the T1c or N0 stages. These findings suggest that ER expression may influence epigenetic changes in early stages of breast cancer.
###end p 64
###begin p 65
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 434 435 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1083 1085 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1116 1121 1116 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH13</italic>
###xml 1123 1128 1123 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOD1</italic>
###xml 1130 1133 1130 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGR</italic>
###xml 1139 1147 1139 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HSD17B4 </italic>
###xml 1227 1230 1227 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1232 1237 1232 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 1243 1251 1243 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 611 619 <span type="species:ncbi:9606">patients</span>
###xml 738 743 <span type="species:ncbi:9606">women</span>
###xml 865 873 <span type="species:ncbi:9606">patients</span>
HER2/neu is another important prognostic marker for breast cancer. HER2/neu gene over-expression is identified in 15% to 25% of invasive breast carcinomas, and is related to metastatic potential and poor survival [35,46]. In our study, HER2/neu over-expression was identified in 27% of breast cancers, and was independent of ER status. A negative relation between ER status and HER2/neu over-expression has been documented by others [9,38,39]. One of the plausible explanations for the lack of difference found in the frequency of HER2/neu-positive tumors between the ER-negative and ER-positive groups is that patients included in the present study were relatively young (average age 51 years). According to Huang and coworkers [38], in women younger than 45 years the inverse association between ER and HER2/neu was not apparent. Of our sample population, 37% of patients were under 45 years old, and this age distribution may explain why we could not detect an inverse relation between ER and HER2/neu status. Regarding gene methylation and HER2/neu status, Fiegl and colleagues [47] reported that methylation of CDH13, MYOD1, PGR, and HSD17B4 exhibited a positive association with HER2/neu expression. We demonstrated that APC, GSTP1, and RASSF1A are more frequently methylated in the HER2/neu over-expressed group. These findings indicate that there are epigenetic differences between HER2/neu breast tumors, and logistic regression analysis showed that these differences are independent of ER status.
###end p 65
###begin p 66
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 580 583 580 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 585 590 585 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 592 599 592 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 605 610 605 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST</italic>
###xml 854 857 854 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 859 864 859 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 870 877 870 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 1324 1326 1324 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1327 1329 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
Clinically, HER2/neu-negative, ER-negative, and PR-negative breast cancers are referred to as triple-negative breast cancers. About 85% of triple-negative breast tumors phenotypes are deemed to be basal-like subtypes, and they are associated with poor clinical outcome [48]. Because the progesterone receptor status of our samples was not well defined, we compared the methylation status of ER-negative and HER2/neu-negative breast tumors (double-negative) with breast cancers expressing either ER or HER2/neu. Double-negative breast tumors exhibited frequent hypermethylation in APC, GSTP1, RASSF1A, and TWIST, revealing the presence of epigenetic differences between double-negative breast tumors and breast cancers expressing either HER2/neu or ER. Furthermore, both ER and HER2/neu status contributed independently to the difference in expression of APC, GSTP1, and RASSF1A. There is evidence that gene expression heterogeneity occurs in basal-like tumors of triple negatives; these subgroups are present with different pathology and clinical properties. Triple negative and ER and HER2/neu-positive status and gene expression levels of tumors may be quite heterogeneous in tumor populations, thus contributing to different subclassifications. Other additional biomarkers may be needed to subclassify phenotypes better [49,50].
###end p 66
###begin p 67
###xml 124 131 124 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 140 145 140 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 147 152 147 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST</italic>
###xml 158 161 158 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 477 482 477 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1 </italic>
###xml 486 490 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 538 543 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 601 605 601 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 607 612 607 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 614 619 614 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 625 629 625 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRb1</italic>
###xml 708 715 708 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 717 722 717 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 724 729 724 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSPT1</italic>
###xml 731 736 731 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TWIST</italic>
###xml 742 746 742 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 770 775 770 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1 </italic>
Another interesting finding is the correlation of methylation status between the tumor-related genes. Methylation status of RASSF1A, CCND2, GSTP1, TWIST, and APC, which was significantly higher in the ER-positive group, was correlated with the methylation status of two or more of the four other genes. Nonrandom distribution of methylation in tumor-related genes has previously been reported; Nass and coworkers [51] and Li and colleagues [45] found coincident methylation of CDH1 and ESR1, and Parrella and coworkers [52] reported that ESR1 promoter hypermethylation status correlates with those of CDH1, GSTP1, CCND2, and TRb1. Our findings revealed that occurrence of promoter region hypermethylation of RASSF1A, CCND2, GSPT1, TWIST, and APC are associated, whereas CDH1 methylation exhibited no correlation with methylation of those five genes (data not shown). This apparent nonrandom distribution of promoter hypermethylation of some genes suggests the existence of specific factors causing selective promoter region hypermethylation of tumor-related genes.
###end p 67
###begin title 68
Conclusion
###end title 68
###begin p 69
###xml 736 737 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
In this study, we demonstrated - for the first time - that epigenetic differences between ER-positive and ER-negative breast tumors arise early in cancer development and persist during cancer progression. Furthermore, we reported epigenetic differences between HER2/neu-positive and HER2/neu-negative breast tumors, and between double-negative breast tumors and breast tumors expressing either HER2/neu or ER. Taking advantage of potential reversibility of DNA methylation, epigenetic therapies directed against various cancers have been in development; 5-azacytidine, 5-aza-2'-deoxycytidines, procainamide, and hydralazine are promising agents. Investigators are attempting to combine epigenetic therapy with other standard therapies [2,53]. For breast cancer, one approach may to combine hormone therapy and antimethylation treatment. Integrated information regarding clinical factors influencing therapeutic principles and epigenetic features, such as promoter hypermethylation of tumor-related genes, will be important for combining epigenetics targeting drugs and standard chemotherapy.
###end p 69
###begin title 70
Abbreviations
###end title 70
###begin p 71
###xml 49 51 49 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">; </sub>
###xml 139 144 <span type="species:ncbi:9606">human</span>
###xml 403 408 <span type="species:ncbi:9606">human</span>
APC, adenomatous polyposis coli; CCND2, cyclin D2; CDH1, E-cadherin; ER, estrogen receptor; GSTP1, glutathione S-transferase P1; HER2/neu, human epidermal growth factor receptor 2; LN, lymph node; MSP, methylation-specific PCR; NES1, normal epithelial cell-specific 1 or kallikrein 10; RARbeta2, retinoic acid receptor- beta2; RASSF1A, RAS association domain family 1A; SLN, sentinel lymph node; TWIST, human basic helix-loop-helix DNA binding protein.
###end p 71
###begin title 72
Competing interests
###end title 72
###begin p 73
The authors have submitted a patent application relating to the content of this manuscript.
###end p 73
###begin title 74
Authors' contributions
###end title 74
###begin p 75
###xml 210 218 <span type="species:ncbi:9606">patients</span>
ES and MS performed methylation assays for the studies. M-SS was the biostatistician in the study. SLN performed assays and assembled the data. A-TV helped with assays. AEG performed the clinical review of the patients and reviewed the study design. DSNH was the principle investigator and designed and reviewed the study.
###end p 75
###begin title 76
Acknowledgements
###end title 76
###begin p 77
This study was funded by the Fashion Footwear Association of New York (FFANY), The Avon Foundation, The Leslie and Susan Gonda (Goldschmied) Foundation, and The Susan G. Komen Breast Cancer Foundation.
###end p 77
###begin article-title 78
Hypermethylation in histologically distinct classes of breast cancer
###end article-title 78
###begin article-title 79
DNA methylation as a therapeutic target in cancer
###end article-title 79
###begin article-title 80
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen
###end article-title 80
###begin article-title 81
###xml 52 60 52 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
The receptor expression pattern in ductal carcinoma in situ predicts recurrence
###end article-title 81
###begin article-title 82
Estrogen receptors: role in breast cancer
###end article-title 82
###begin article-title 83
Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations
###end article-title 83
###begin article-title 84
###xml 50 55 <span type="species:ncbi:9606">women</span>
Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison
###end article-title 84
###begin article-title 85
Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status
###end article-title 85
###begin article-title 86
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
###end article-title 86
###begin article-title 87
Risk factors for breast cancer according to estrogen and progesterone receptor status
###end article-title 87
###begin article-title 88
Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups
###end article-title 88
###begin article-title 89
Concordance among gene-expression-based predictors for breast cancer
###end article-title 89
###begin article-title 90
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumours
###end article-title 90
###begin article-title 91
Identification of the E1A-regulated transcription factor p120 E4F as an interacting partner of the RASSF1A candidate tumor suppressor gene
###end article-title 91
###begin article-title 92
Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma
###end article-title 92
###begin article-title 93
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression
###end article-title 93
###begin article-title 94
###xml 47 52 <span type="species:ncbi:9606">human</span>
Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma
###end article-title 94
###begin article-title 95
###xml 69 74 <span type="species:ncbi:9606">human</span>
Role of the Ras-association domain family 1 tumor suppressor gene in human cancers
###end article-title 95
###begin article-title 96
RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression
###end article-title 96
###begin article-title 97
A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability
###end article-title 97
###begin article-title 98
Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation
###end article-title 98
###begin article-title 99
Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation
###end article-title 99
###begin article-title 100
Nutrition and breast cancer
###end article-title 100
###begin article-title 101
Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis
###end article-title 101
###begin article-title 102
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
###end article-title 102
###begin article-title 103
###xml 68 76 68 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma
###end article-title 103
###begin article-title 104
Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers
###end article-title 104
###begin article-title 105
Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas
###end article-title 105
###begin article-title 106
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability
###end article-title 106
###begin article-title 107
Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression
###end article-title 107
###begin article-title 108
The role for NES1 serine protease as a novel tumor suppressor
###end article-title 108
###begin article-title 109
Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung
###end article-title 109
###begin article-title 110
Clinical trials with retinoids for breast cancer chemoprevention
###end article-title 110
###begin article-title 111
Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype
###end article-title 111
###begin article-title 112
Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome
###end article-title 112
###begin article-title 113
The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy
###end article-title 113
###begin article-title 114
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
###end article-title 114
###begin article-title 115
###xml 74 79 <span type="species:ncbi:9606">women</span>
Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer
###end article-title 115
###begin article-title 116
Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle
###end article-title 116
###begin article-title 117
###xml 105 110 <span type="species:ncbi:9606">human</span>
Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines
###end article-title 117
###begin article-title 118
Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis
###end article-title 118
###begin article-title 119
Epigenetic information and estrogen receptor alpha expression in breast cancer
###end article-title 119
###begin article-title 120
Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer
###end article-title 120
###begin article-title 121
DNA hypermethylation in breast cancer and its association with clinicopathological features
###end article-title 121
###begin article-title 122
###xml 43 48 <span type="species:ncbi:9606">human</span>
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
###end article-title 122
###begin article-title 123
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer
###end article-title 123
###begin article-title 124
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry
###end article-title 124
###begin article-title 125
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
###end article-title 125
###begin article-title 126
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
###end article-title 126
###begin article-title 127
###xml 116 121 <span type="species:ncbi:9606">human</span>
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer
###end article-title 127
###begin article-title 128
Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors
###end article-title 128
###begin article-title 129
Epigenetic therapy of cancer: past, present and future
###end article-title 129

